Cargando…

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Background: Since limited data are available, we aimed to compare the efficacy and durability of dolutegravir and darunavir in advanced naïve patients. Methods: Retrospective multicenter study including AIDS- or late-presenting (def. CD4 ≤ 200/µL) HIV-infected patients starting dolutegravir or riton...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabbiani, Massimiliano, Masini, Melissa, Rossetti, Barbara, Ciccullo, Arturo, Borghi, Vanni, Lagi, Filippo, Capetti, Amedeo, Colafigli, Manuela, Panza, Francesca, Baldin, Gianmaria, Mussini, Cristina, Sterrantino, Gaetana, Farinacci, Damiano, Montagnani, Francesca, Tumbarello, Mario, Di Giambenedetto, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224150/ https://www.ncbi.nlm.nih.gov/pubmed/37243208 http://dx.doi.org/10.3390/v15051123

Ejemplares similares

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort
por: Ciccullo, Arturo, et al.
Publicado: (2022)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Shall We Dance? Extending TANGO’s Results to Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2020)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience
por: Mazzitelli, Maria, et al.
Publicado: (2021)

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2021)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
por: Borghetti, Alberto, et al.
Publicado: (2019)

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019)

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study
por: Lombardi, Francesca, et al.
Publicado: (2023)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study
por: Latini, Alessandra, et al.
Publicado: (2016)

Primary Cutaneous Cryptococcosis in an Immunocompetent Patient: Diagnostic Workflow and Choice of Treatment
por: Panza, Francesca, et al.
Publicado: (2023)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
por: Capetti, Amedeo F, et al.
Publicado: (2019)

Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
por: Lombardi, Francesca, et al.
Publicado: (2021)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
por: Panza, Francesca, et al.
Publicado: (2023)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV
por: Donne, Valentina Delle, et al.
Publicado: (2022)

Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report
por: Passerotto, Rosa Anna, et al.
Publicado: (2023)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy
por: Lombardi, Francesca, et al.
Publicado: (2021)

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study
por: Lombardi, Francesca, et al.
Publicado: (2016)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition
por: Delle Donne, Valentina, et al.
Publicado: (2020)

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals
por: Hawkins, Kellie, et al.
Publicado: (2018)

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
por: Verna, John, et al.
Publicado: (2018)

Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study
por: Weidlich, Simon, et al.
Publicado: (2020)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
por: Jabłonowska, Elżbieta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pugistbkundf250fp663vl8b4q